It is known that patients who are not BRCA1/2 pathogenic or likely-pathogenic variant carriers but have a homologous recombination deficiency (HRD) benefit from additional treatment with PARP inhibitors [25]. Here, BRCA1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.